InVivo Therapeutics (NSDQ:NVIV) shares are up this morning on the spinal scaffold maker’s announcement that it enrolled the 6th patient in its Inspire pivotal clinical trial.
The patient, who’s being treated at the Barnes-Jewish Hospital at Washington University Medical Center in St. Louis, Mo., was implanted with the InVivo device about 10 hours after a traumatic spinal injury, the Cambridge, Mass.-based company said.
“We were able to get the patient into the operating room in such an expeditious manner, thanks to the experienced trauma and neurosurgical teams at the Barnes-Jewish Hospital,” said Dr. Wilson “Zack” Ray, a member of the Inspire study’s steering committee, in prepared remarks. “The implantation procedure was straightforward and the patient is recovering well. I look forward to following the patient’s progress.”
“Once again, it has been demonstrated that neuro-spinal scaffold implantation is readily performed within 12 hours post-injury, which is earlier than most standard of care spine stabilization surgery. We look forward to diligently monitoring this patient’s outcomes and enrolling additional patients into this landmark study,” InVivo chairman & CEO Mark Perrin said.
NVIV shares were up 5.1% to $4.96 apiece today in mid-morning trading.
Last month, InVivo Therapeutics said it won FDA approval to shift the Inspire pilot trial of its spinal scaffold to a pivotal probable benefit study. Earlier this month, the company added the University of California’s San Diego Medical Center as a site for the Inspire trial.
